Tags

Type your tag names separated by a space and hit enter

Molecular characterization of endometrial cancer and therapeutic implications.
Curr Opin Obstet Gynecol. 2019 02; 31(1):24-30.CO

Abstract

PURPOSE OF REVIEW

The present article reviews genomic subtyping of endometrial carcinoma and new molecular markers with therapeutic and prognostic implications.

RECENT FINDINGS

Endometrial cancer has historically been classified through histology into endometrioid (type 1) and nonendometrioid (type II, mainly serous) subtypes. Molecular classification through genomic analysis now allows for a major advance in characterization; four distinct subgroups have been identified: polymerase ε (POLE) ultramutated, microsatellite unstable, copy number low/microsatellite stable, and copy number high/'serous-like'. These subtypes have prognostic implications and may aid in the identification of early-stage patients who are at high risk for recurrence. Through analysis of surrogate markers (POLE, MSI, and p53) and other validated molecular alterations (L1CAM), it may be possible to obtain an integrated molecular risk profile. Ongoing studies are utilizing this risk profile in order to identify patients who may benefit from additional treatment for early-stage disease.

SUMMARY

Molecular characterization of endometrial cancer into subgroups has prognostic and therapeutic implications. Further development of an integrated molecular risk profile may identify patients who could benefit from additional treatment because of a higher risk of recurrence.

Authors+Show Affiliations

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota School of Medicine.Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota School of Medicine.Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota School of Medicine.Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota School of Medicine. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30507624

Citation

Chang, Zenas, et al. "Molecular Characterization of Endometrial Cancer and Therapeutic Implications." Current Opinion in Obstetrics & Gynecology, vol. 31, no. 1, 2019, pp. 24-30.
Chang Z, Talukdar S, Mullany SA, et al. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol. 2019;31(1):24-30.
Chang, Z., Talukdar, S., Mullany, S. A., & Winterhoff, B. (2019). Molecular characterization of endometrial cancer and therapeutic implications. Current Opinion in Obstetrics & Gynecology, 31(1), 24-30. https://doi.org/10.1097/GCO.0000000000000508
Chang Z, et al. Molecular Characterization of Endometrial Cancer and Therapeutic Implications. Curr Opin Obstet Gynecol. 2019;31(1):24-30. PubMed PMID: 30507624.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Molecular characterization of endometrial cancer and therapeutic implications. AU - Chang,Zenas, AU - Talukdar,Shobhana, AU - Mullany,Sally A, AU - Winterhoff,Boris, PY - 2018/12/7/pubmed PY - 2019/11/28/medline PY - 2018/12/4/entrez SP - 24 EP - 30 JF - Current opinion in obstetrics & gynecology JO - Curr Opin Obstet Gynecol VL - 31 IS - 1 N2 - PURPOSE OF REVIEW: The present article reviews genomic subtyping of endometrial carcinoma and new molecular markers with therapeutic and prognostic implications. RECENT FINDINGS: Endometrial cancer has historically been classified through histology into endometrioid (type 1) and nonendometrioid (type II, mainly serous) subtypes. Molecular classification through genomic analysis now allows for a major advance in characterization; four distinct subgroups have been identified: polymerase ε (POLE) ultramutated, microsatellite unstable, copy number low/microsatellite stable, and copy number high/'serous-like'. These subtypes have prognostic implications and may aid in the identification of early-stage patients who are at high risk for recurrence. Through analysis of surrogate markers (POLE, MSI, and p53) and other validated molecular alterations (L1CAM), it may be possible to obtain an integrated molecular risk profile. Ongoing studies are utilizing this risk profile in order to identify patients who may benefit from additional treatment for early-stage disease. SUMMARY: Molecular characterization of endometrial cancer into subgroups has prognostic and therapeutic implications. Further development of an integrated molecular risk profile may identify patients who could benefit from additional treatment because of a higher risk of recurrence. SN - 1473-656X UR - https://www.unboundmedicine.com/medline/citation/30507624/Molecular_characterization_of_endometrial_cancer_and_therapeutic_implications_ L2 - https://doi.org/10.1097/GCO.0000000000000508 DB - PRIME DP - Unbound Medicine ER -